Veteleanu, Aurora
Stevenson-Hoare, Joshua
Keat, Samuel
Daskoulidou, Nikoleta
Zetterberg, Henrik
Heslegrave, Amanda
Escott-Price, Valentina
Williams, Julie
Sims, Rebecca
Zelek, Wioleta M.
Carpanini, Sarah M.
Morgan, Bryan Paul
Funding for this research was provided by:
Medical Research Council (UKDRI-3003)
Article History
Received: 17 April 2023
Accepted: 8 July 2023
First Online: 21 July 2023
Declarations
:
: Ethical approval was obtained from the Multi-centre Research Ethics Committee, relevant local ethics committees and NHS trusts in the recruiting regions.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). BPM serves as a consultant for Kira Pharmaceuticals and as an advisory board member for Complement Therapeutics.